Ropes & Gray represented Matchpoint Therapeutics in an exclusive option and license agreement with Novartis for the development and commercialization of oral covalent inhibitors directed at a transcription factor linked to multiple inflammatory diseases. The transaction was announced on July 24.
Under the agreement, Matchpoint will use its Advanced Covalent Exploration platform to advance its preclinical program through development candidate selection. Matchpoint will lead all research to that point and will receive up to $60 million in upfront payment and research funding from Novartis. If Novartis exercises its option to exclusively license the program, Novartis will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint is eligible to receive up to $1 billion in total payments, including development and commercial milestones, plus tiered royalties on future product sales.
The Ropes & Gray team was led by life sciences licensing partner David McIntosh and life sciences licensing associate Ian Nilsen and included tax partner David Saltzman, litigation & enforcement partner Jackie Grise and tax associate Elizabeth Sun.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
